Adherus AutoSpray Dural Sealant
Stryker Leibinger GmbH & Co. KG · Decision date Nov 6, 2025
What did the FDA approve?
FDA records P130014/S021 as a supplement to PMA P130014, with the supplement type “135 Review Track For 30-Day Notice”. The recorded decision is approval, dated Nov 6, 2025.
FDA approval order statement
Approval for use of an automated vial filling system and to perform a packaging step outside of a glove box.
- Regulatory pathway
- PMA supplement
- Supplement type
- 135 Review Track For 30-Day Notice
- Clinical specialty
- Neurology
- Decision date
- Nov 6, 2025
- FDA change category
- Process Change - Manufacturer/Sterilizer/Packager/Supplier
Regulatory record facts
- Identifier
- P130014/S021
- Regulatory pathway
- PMA supplement
- Applicant
- Stryker Leibinger GmbH & Co. KG
- Product code
- NQR
- Decision code
- APPR
- Decision date
- Nov 6, 2025
- Source update
- Nov 9, 2026
- Original record
- Open FDA source record
About this medical device
FDA device category: Sealant, dural.
- Applicant
- Stryker Leibinger GmbH & Co. KG
- Product code
- NQR
- FDA device class
- 3
Review the original FDA PMA listing for the original approval scope and linked supplements.
FDA decision timeline
P130014/S021 received
Application receipt date recorded by FDA.
P130014/S021 · FDA decision
135 Review Track For 30-Day Notice
P130014/S022 · Related supplement
Adherus AutoSpray Dural Sealant; Adherus AutoSpray ET Dural Sealant
Timeline entries are records held by MedtechLedger for P130014. View FDA’s full supplement list.
Related devices and submissions
Same PMA: P130014
| Product / regulatory record | Company | Pathway | Decision date | Source |
|---|---|---|---|---|
| Stryker Leibinger GmbH & Co. KG | PMA supplement | Jul 15, 2026 | FDA |
Explore the linked device profile
Other records with product code NQR
| Product / regulatory record | Company | Pathway | Decision date | Source |
|---|---|---|---|---|
CraniSeal Dural SealantP220014/S013 | Pramand, LLC | PMA supplement | Oct 1, 2026 | FDA |
SpineSeal Spine SealantP240027/S007 | Pramand, LLC | PMA supplement | Sep 11, 2026 | FDA |
SpineSeal Spine SealantP240027/S006 | Pramand, LLC | PMA supplement | Aug 31, 2026 | FDA |
CraniSeal Dural SealantP220014/S012 | Pramand, LLC | PMA supplement | Aug 5, 2026 | FDA |
CraniSeal Dural SealantP220014/S011 | Pramand, LLC | PMA supplement | Apr 1, 2026 | FDA |
A shared product code identifies a classification relationship; it does not establish clinical equivalence.
Regulatory context
A PMA supplement records a change to a device with an existing premarket approval. The supplement’s approval applies to the change described in that submission.
Read our guide to FDA clearance and approval · FDA’s explanation of this pathway
Manufacturer intelligence
Stryker Leibinger GmbH & Co. KG
- Headquarters
- Not reported
- Brand website
- stryker.com
- FDA applicant address
- Boetzinger Strasse 41, Freiburg, D-7911
Sources and methodology
- Original FDA record: P130014/S021
- openFDA source data · Source release Nov 9, 2026 · Retrieved Nov 20, 2026
FDA fields and approval-order wording are presented as source information. MedtechLedger explanations are identified separately and describe the scope of the recorded decision. Indications from an original PMA are historical unless confirmed against subsequent labeling and supplements.
How we use FDA records



